%0 Journal Article %T Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects %+ Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER) %+ CHU Lille %+ Lille Neurosciences & Cognition - U 1172 (LilNCog) %+ Excellence Laboratory LabEx DISTALZ %+ Michigan State University [East Lansing] %+ Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) %+ Impact de l'environnement chimique sur la santé humaine - ULR 4483 (IMPECS) %+ University of Coimbra [Portugal] (UC) %+ Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (EGENODIA (GI3M)) %+ European Genomic Institute for Diabetes - FR 3508 (EGID) %+ Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE) %A Dewaeles, Edmone %A Carvalho, Kévin %A Fellah, Sandy %A Sim, Jaewon %A Boukrout, Nihad %A Caillierez, Raphaelle %A Ramakrishnan, Hariharan %A van der Hauwaert, Cynthia %A Vijaya Shankara, Jhenkruthi %A Martin, Nathalie %A Massri, Noura %A Launay, Agathe %A Folger, Joseph %A de Schutter, Clémentine %A Larrue, Romain %A Loison, Ingrid %A Goujon, Marine %A Jung, Matthieu %A Le Gras, Stéphanie %A Gomez-Murcia, Victoria %A Faivre, Emilie %A Lemaire, Julie %A Garat, Anne %A Beauval, Nicolas %A Maboudou, Patrice %A Gnemmi, Viviane %A Gibier, Jean-Baptiste %A Buée, Luc %A Abbadie, Corinne %A Glowacki, Francois %A Pottier, Nicolas %A Perrais, Michael %A Cunha, Rodrigo %A Annicotte, Jean-Sébastien %A Laumet, Geoffroy %A Blum, David %A Cauffiez, Christelle %< avec comité de lecture %@ 1558-8238 %J The Journal of clinical investigation %V 132 %N 22 %P e152924 %8 2022-11-15 %D 2022 %R 10.1172/JCI152924 %M 36377661 %K G protein–coupled receptors %K Nephrology %K Pharmacology %Z Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyJournal articles %X Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. %G English %2 https://www.hal.inserm.fr/inserm-03865945/document %2 https://www.hal.inserm.fr/inserm-03865945/file/TJClinInvestig2022_152924.pdf %L inserm-03865945 %U https://www.hal.inserm.fr/inserm-03865945 %~ INSERM %~ RIIP %~ CNRS %~ IGBMC %~ UNIV-STRASBG %~ SITE-ALSACE %~ UNIV-LILLE %~ CANTHER